Results 61 to 70 of about 907 (150)

Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities

MedComm, Volume 7, Issue 5, May 2026.
This graphical abstract summarizes how classical and emerging histone posttranslational modifications (PTMs), together with their chromatin regulators (writers, erasers, and readers), govern major pathobiological programs in cardiovascular disease.
Yu Zheng, Yu‐Xuan Gao, Mei‐Xing Guo, Li‐Ting Wang, Xiao‐Wen Zheng, Yi‐Hao Liao, Ya Li, Jun‐Ping Zhu, Jia‐Ming Wei   +8 more
wiley   +1 more source

Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies

Clinical and Translational Medicine
Early detection of gastrointestinal (GI) cancers remains a critical unmet clinical need, as most patients are diagnosed at advanced stages when prognosis is poor.
Muhammad Anees, Christopher Sherry, Hyun Y. Park, Erin E. Grayhack, Arul Goel, Alisha F. Khan, Ashten Omstead, David L. Bartlett, Ajay Goel, Neda Dadgar, Patrick L. Wagner, Ali H. Zaidi   +11 more
doaj   +1 more source

Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025

Cancer Innovation, Volume 5, Issue 2, April 2026.
This review summarizes key breakthrough advances in hepatocellular carcinoma (HCC) reported in 2025 and presents a multidisciplinary management framework for HCC, integrating early diagnosis, microenvironment insights, and comprehensive therapeutic strategies spanning minimally invasive surgery, locoregional interventions, and systemic pharmacotherapy.
Bo Hu, Qiang Gao
wiley   +1 more source

Cell-Free DNA Fragmentomics: The New “Omics” on the Block [PDF]

Clinical Chemistry, 2020
Rossa W K Chiu, Ellen Heitzer, Y M Dennis Lo, Florent Mouliere, Dana W Y Tsui   +4 more
openaire   +1 more source

Whole‐genome sequencing of cell‐free DNA for assessment of minimal residual disease in high‐risk smoldering multiple myeloma

HemaSphere, Volume 10, Issue 4, April 2026.
Abstract In multiple myeloma (MM), minimal residual disease (MRD) is an established endpoint for accelerated drug approval but is limited by a need for serial invasive bone marrow (BM) biopsies, which may under‐sample spatial heterogeneity and result in false negativity.
Chrissy Baker, Elizabeth Hill, Dickran Kazandjian, Marios Papadimitriou, Michael Durante, Abhishek Pandey, Bachisio Ziccheddu, Tomas Jelinek, David Coffey, Brian Walker, Ryan Young, Kylee Maclachlan, Neha Korde, Nickoli Parkinson, Zoe R. Goldstein, Alexi Runnels, William F. Hooper, Dan Landau, Nicolas Robine, Francesco Maura, Ola Landgren, Benjamin Diamond   +21 more
wiley   +1 more source

USP44, ZNF454, and GPRC5B ctDNA Methylation Markers in Breast Cancer: Limited Clinical Relevance for Disease Monitoring and Tumor Characteristics

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 260-269, April 2026.
We selected breast cancer‐specific DNA methylation markers using The Cancer Genome Atlas (TCGA). We analyzed the methylation and expression patterns of candidate genes in breast cancer cell lines, ctDNA, and tissue samples. The relationship between ctDNA methylation markers and the clinicopathological features of breast cancer patients was investigated.
Young Ju Jeong, Chang‐Ho Jeon, Hoon Kyu Oh, Jeong Kyu Kim, Chun‐Seok Yang, Na‐Rang Lee, Doyeon Kim   +6 more
wiley   +1 more source

From detection to action: ctDNA-MRD surveillance and translational strategies in early breast cancer

Frontiers in Oncology
Recurrence remains a major cause of mortality in early breast cancer (EBC), and conventional follow-up often identifies relapse only after clinically detectable disease has emerged. Circulating tumor DNA–based minimal residual disease (ctDNA-MRD) testing
Jing Feng, Yujun Tong, Zhen Zhang, Ye Zhang   +3 more
doaj   +1 more source

Cancer-Like Fragmentomic Characteristics of Somatic Variants in Cell-Free DNA. [PDF]

Adv Sci (Weinh)
ABSTRACT Cell‐free DNA (cfDNA) in plasma consists of short DNA fragments resulting from a non‐random fragmentation process, with distinct fragmentomic characteristics that are related with their cellular origins. Here, we report that somatic variant signatures in cfDNA markedly differ between non‐cancerous controls and cancer patients,
Zhang Z, An Y, Yang M, Pan Y, Liu X, Gong F, Lin H, Tang B, Bai Y, Zhao X, Zhao Y, Du C, Sun K.   +12 more
europepmc   +3 more sources

Macromolecular Fragmentation on the Skin Surface: Formation Mechanisms, Evidence Limitations, and Potential Relevance for Skin Homeostasis

Cosmetics
The skin surface is a dynamic biochemical interface where proteins, polysaccharides, lipids, and microbial or environmental molecules are continuously exposed to ultraviolet(UV) radiation, oxidative stress, mechanical stimulation, pH variation, host ...
Keran Jia, Xiao Ning, Liya Song, Jin Cao
doaj   +1 more source

Leveraging cfDNA fragmentomic features for the early detection of colorectal cancer

Frontiers in Immunology
Background Early detection of colorectal cancer (CRC) is crucial for improving patient outcomes. Cell-free DNA (cfDNA) analysis has emerged as a promising non-invasive approach for cancer detection. This study aims to develop a machine learning algorithm leveraging cfDNA fragmentomic features to accurately ...
Shan, Lina, Xu, Dengyong, Chen, Jie, Liu, Wenjia, Lin, Ji, Bao, Juhang, Huang, Jianfei, Zhang, Hanqing, Zhao, Hanchen, Xue, Wei, Lin, Ziao, Bai, Bingjun   +11 more
openaire   +2 more sources